Q4 2025 Xvivo Perfusion AB Earnings Call Transcript
Key Points
- Xvivo Perfusion AB (XVIPF) reported a 10% topline organic growth in Q4 2025, indicating a strong recovery in sales.
- The company achieved a record quarter in the abdominal segment, with liver sales growing 36% in Q4 and 31% for the full year.
- Xvivo Perfusion AB (XVIPF) has successfully expanded its sales force footprint in Europe, particularly in the liver segment, achieving 25% penetration in core EU markets.
- The company has made significant progress in its heart technology, with more than 500 patients safely transplanted using heart assist, and strong interest from clinics in Europe and Australia.
- Xvivo Perfusion AB (XVIPF) achieved a new record with an EBITA margin of 25% in Q4, driven by increased sales and a strong focus on operating expenses.
- The US service business needs drastic improvement, with negative organic growth of 21% in Q4.
- The company's gross margin decreased to 73% in Q4 due to inventory write-offs related to R&D projects.
- Regulatory approval for heart technology remains a hurdle, with timelines being hard to predict.
- The kidney segment is still below 15% penetration in many countries, including the US, indicating room for improvement.
- Currency fluctuations, particularly a weakened US dollar, pose a risk to future sales and profitability.
To Xvivo Q4 report for 2025 for the first part of the conference call, the participants will be in listen-only mode. During the questions and answer session. Participants are able to ask questions by dialing pound 5 on their telephone keypad. Now I will hand the conference over to Chief Executive Officer Christoffer Rosenblad and CFO Kristoffer Nordstrom. Please go ahead.
Thank you so much. Good morning and good afternoon and most of all, welcome to Xvivo earnings call for the fourth quarter as well as for the full year of 2025.
And with that, we turn over to slide 2. It's just the two presenters that were introduced. It's me, Christopher Rosenblatt, calling in from Gothenburg, and the company CFO Christopher Nordstrom calling in from Philly in the United States.
And with that we can go over to slide 3, which are the Q4 financial at the glance.
The Q4 shows 10%% topline organic growth if we adjust for the US art trial revenue compared to Q4 last year.
With
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
